

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p>			Complete if Known	
			Application Number	09/780,016
			Filing Date	Feb 9, 2001
			First Named Inventor	Donoho
			Group Art Unit	1645
			Examiner Name	To Be Assigned
Shee	(use as many sheets as necessary)	1	Attorney Docket Number	LEX-0132-USA

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ³ (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ³ (if known)			
Up	CB	WO 99/11799		Medical College of Georgia Res Inst	03-11-1999	Figures Appear	
Up	CC	WO 99/64576		Bayer Corporation	12-16-1999		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
Up	CD	MARRA ET AL.: "uj15b03.y1 Sugano mouse kidney mkia Mus musculus cDNA clone IMAGE: 1908149 5' similar to SW:YEQ8_YEAST P40051 HYPOTHETICAL 58.0 KD PEPTIDASE IN ARG5, 6-ILV1 INTERGENIC REGION; mRNA sequence: EMBL SEQUENCE DATABASE, 31 October 1998, XP002171875				
Up	CE	MATTHEWS, L: "Human DNA sequence from clone RP5-1057d18 on chromosome 22q13.33 Contains the gene for a novel protein similar to yeast and bacterial PEPP (aminopeptidase P, aminoacylproline aminopeptidase), ESTs and GSSs" EMBL SEQUENCE DATABASE, 24 February 1999, XP002171876				
Up	CF	COLLINS ET AL.: "Novel human gene mapping to chromosome 22", EMBL SEQUENCE DATABASE, 12 July 2000, XP002171877				
Up	CG	COLLINS ET AL.: "Hypothetical 58.0 kD protein". SWISSPROT SEQUENCE DATA BASE, 1 October 2000, XP002171878				

Examiner Signature	Up	Date Considered	12/10/04
--------------------	----	-----------------	----------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>				Application Number	09/780,016
				Filing Date	February 9, 2001
				First Named Inventor	Donoho, Gregory
				Group Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	1	of	3	Attorney Docket Number	LEX-0132-USA

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
Uf	AA	4,215,051		Schroeder et al	07/29/80	
	AB	4,376,110		David et al	03/08/83	
	AC	4,594,595		Struckman	06/10/86	
	AD	4,631,211		Houghten	12/23/86	
	AE	4,689,405		Frank et al	08/25/87	
	AF	4,713,326		Dattagupta et al	12/15/87	
	AG	4,946,778		Ladner et al	08/07/90	
	AH	5,252,743		Barrett et al	10/12/93	
	AI	5,424,186		Fodor et al	08/13/95	
	AJ	5,445,934		Fodor et al	08/29/95	
	AK	5,459,127		Felgner et al	10/17/95	
	AL	5,556,752		Lockhart et al	09/17/96	
	AM	5,656,603		Simmons	08/12/97	
	AN	5,700,637		Southern	12/23/97	
	AO	5,744,305		Fodor et al	04/28/98	
	AP	5,869,336		Meyer et al.	02/09/99	
	AQ	5,877,397		Lonberg et al	03/02/99	
	AR	5,948,767		Scheule et al.	09/07/99	
	AS	5,972,680		Knowles et al.	10/26/99	
	AT	6,075,181		Kucherlapati et al	06/13/00	
	AU	6,110,490		Thierry	08/29/00	
Ch	AV	6,150,584		Kucherlapati et al.	11/21/00	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			

Examiner Signature		Date Considered	12/16/04
--------------------	---	-----------------	----------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/780,016
Sheet	2	of	3	Filing Date	February 9, 2001
				First Named Inventor	Donoho, Gregory
				Group Art Unit	1645
				Examiner Name	To Be Assigned
				Attorney Docket Number	LEX-0132-USA

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
YD	AW	Bird et al, 1988, "Single-Chain Antigen-Binding Proteins", Science 242:423-426.			
	AX	Bitter et al, 1987, "Expression and Secretion Vectors for Yeast", Methods in Enzymology 153:516-544.			
	AY	Colbere-Garapin et al, 1981, "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells", J. Mol. Biol. 150:1-14.			
	AZ	Gautier et al, 1987, "α-DNA IV:α-anomeric and β-anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physiochemical properties and poly (rA) binding", Nucleic Acids Research 15(16):6625-6641.			
	BA	Greenspan et al, 1993, "Idiotypes: structure and immunogenicity", FASEB Journal 7:437-444.			
	BB	Huse et al, 1989, "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda", Science 246:1275-1281.			
	BC	Huston et al, 1988, "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli", Proc. Natl. Acad. Sci. USA 85:5879-5883.			
	BD	Inoue et al, 1987, "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and R Nase H", FEBS Letters 215(2):327-330.			
	BE	Inoue et al, 1987, "Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides", Nucleic Acids Research 15(15):6131-6149.			
	BF	Inouye & Inouye, 1985, "Up-promoter mutations in the lpp gene of Escherichia coli", Nucleic Acids Research 13(9):3101-3110.			
	BG	Janknecht et al, 1991, "Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus", PNAS 88:8972-8976.			
	BH	Kohler & Milstein, 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity", Nature 256:495-497.			
	BI	Logan et al, 1984, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection", Proc. Natl. Acad. Sci. USA 81:3655-3659.			
	BJ	Lowy et al, 1980, "Isolation of Transforming DNA: Cloning the Hamster apt Gene", Cell 22:817-823.			
	BK	Morrison et al, 1984, "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains", Proc. Natl. Acad. Sci. USA 81:6851-6855.			
	BL	Mulligan & Berg, 1981, "Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase", Proc. Natl. Acad. Sci. USA 78(4):2072-2076.			
	BM	Neuberger et al, 1984, "Recombinant antibodies possessing novel effector functions", Nature 312:604-608.			
	BN	Nisonoff, 1991, "Idiotypes: Concepts and Applications", J. of Immunology 147:2429-2438.			
	BO	O'Hare et al, 1981, "Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase", Proc. Natl. Acad. Sci. USA 78(3):1527-1531.			
	BP	Ripka, 1988, "Computers picture the perfect drug", New Scientist 16:54-57.			
	BQ	Ruther et al, 1983, "Easy identification of cDNA clones", EMBO Journal 2(10):1791-1794.			
	BR	Santerre et al, 1984, "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells", Gene 30:147-156.			
	BS	Sarin et al, 1988, "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates", Proc. Natl. Acad. Sci. USA 85:7448-7451.			
	BT	Smith et al, 1983, "Molecular Engineering of the <i>Autographa californica</i> Nuclear Polyhedrosis Virus Genome: Deletion Mutations within the Polyhedrin Gene", J. Virol. 46(2):584-593.			
YD	BU	Stein et al, 1988, "Physiochemical properties of phosphorothioate oligodeoxynucleotides", Nucleic Acids Research 16(8):3209-3221.			

YD 12/10/04

inside this box →

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/780,016
				Filing Date	February 9, 2001
				First Name and Inventor	Donoho, Gregory
				Group Art Unit	1645
				Examiner Name	To Be Assigned
(use as many sheets as necessary)				Attorney Docket Number	LEX-0132-USA
Shee	3	of	3		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
4p	BV	Szybalska & Szybalski, 1962, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026-2034.			
	BW	Takeda et al, 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", Nature 314:452-454.			
	BX	Van Heeke et al, 1989, "Expression of Human Asparagine Synthetase in Escherichia coli", J. Biol. Chemistry 264(10):5503-5509.			
	BY	Ward et al, 1989, "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli", Nature 341:544-546.			
	BZ	Wigler et al, 1977, "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", Cell 11:223-232.			
dpv	CA	Wigler et al, 1980, "Transformation of mammalian cells with an amplifiable dominant-acting gene", Proc. Natl. Acad. Sci. USA 77(6):3567-3570.			

Examiner Signature	<i>G. P.</i>	Date Considered	12/16/04
--------------------	--------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.